Last reviewed · How we verify
Long- and intermediate- acting insulins — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Long- and intermediate- acting insulins (Long- and intermediate- acting insulins) — Biologics & Biosimilars Collective Intelligence Consortium.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Long- and intermediate- acting insulins TARGET | Long- and intermediate- acting insulins | Biologics & Biosimilars Collective Intelligence Consortium | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Long- and intermediate- acting insulins CI watch — RSS
- Long- and intermediate- acting insulins CI watch — Atom
- Long- and intermediate- acting insulins CI watch — JSON
- Long- and intermediate- acting insulins alone — RSS
Cite this brief
Drug Landscape (2026). Long- and intermediate- acting insulins — Competitive Intelligence Brief. https://druglandscape.com/ci/long-and-intermediate-acting-insulins. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab